前收市價 | 182.79 |
開市 | 182.58 |
買盤 | 180.73 x 1000 |
賣出價 | 181.10 x 100 |
今日波幅 | 180.01 - 184.10 |
52 週波幅 | 125.82 - 298.95 |
成交量 | |
平均成交量 | 939,008 |
市值 | 12.683B |
Beta 值 (5 年,每月) | 0.99 |
市盈率 (最近 12 個月) | 54.38 |
每股盈利 (最近 12 個月) | 3.33 |
業績公佈日 | 2024年8月06日 - 2024年8月12日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 232.90 |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
On Tuesday, Blue Orca Capital released a report on Insulet Corporation (NASDAQ:PODD), saying it is short on the insulin delivery patch pump manufacturer. The report added that Blue Orca is long on its upstart Korean competitor EOFlow Co Ltd as last week the Court of Appeals for the Federal Circuit killed a preliminary injunction that protected Insulet’s key monopoly against competition from EOFlow. The report adds that the injunction is undisclosed to investors. The report notes, “In our opinion
Wall Street is experiencing a subdued trading session, with all major indices showing minimal movement around midday in New York. The latest producer inflation data provided mixed signals ahead of the highly anticipated consumer inflation report on Wednesday. Fed Chair Jerome Powell reiterated his outlook that U.S. monetary policy will maintain its current rate for a longer period than previously anticipated, dismissing fears of new rate hikes. President Joe Biden announced significant tariffs o